Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Telix Pharmaceuticals Ltd
TLXCurrent price
15.35 USD
-0.1 USD (-0.65%)
Last closed
24.84 AUD
Company
telixpharma.com
ISIN
AU000000TLX2
Sector
Healthcare
Industry
Biotechnology
Exchange
AU
Capitalization
8 793 287 655 AUD
Yield for 12 month
+138.68 %
1Y
3Y
5Y
10Y
15Y
TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia. Address: 55 Flemington Road, North Melbourne, VIC, Australia, 3051
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
41.55 AUDP/E ratio
170.20Dividend Yield
–Current Year
+511 060 036 AUD
Last Year
+164 738 115 AUD
Current Quarter
+194 442 137 AUD
Last Quarter
+289 881 500 AUD
Current Year
+317 447 269 AUD
Last Year
+30 187 651 AUD
Current Quarter
+127 473 033 AUD
Last Quarter
+230 469 339 AUD
Key Figures TLX
1 year
3 years
5 years
10 years
EBITDA
75 262 812 AUD
Operating Margin TTM
PE Ratio
170.20
Return On Assets TTM
7.97 %
PEG Ratio
–
Return On Equity TTM
20.49 %
Wall Street Target Price
41.55 AUD
Revenue TTM
664 398 928 AUD
Book Value
1.24 AUD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
58.10 %
Dividend Yield
–
Gross Profit TTM
101 397 248 AUD
Earnings per share
0.15 AUD
Diluted Eps TTM
0.15 AUD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
7.62 %
Dividend Analytics TLX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History TLX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation TLX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
170.20
Forward PE
77.52
Enterprise Value Revenue
12.95
Price Sales TTM
13.24
Enterprise Value EBITDA
113.08
Price Book MRQ
20.66
Financials TLX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators TLX
For 52 weeks
9.39 AUD
26.02 AUD
50 Day MA
23.44 AUD
Shares Short Prior Month
–
200 Day MA
18.91 AUD
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart